Errata

Volume 40, No. 2, page 858: On the right column, the paragraph starting with “Patients were required..6 low adherence (18, 19)” should be replaced by the following:

Patients were required to be able to complete a self-reported demographic questionnaire and the validated Morisky Medication Adherence Scale questionnaire (MMAS-8), in either English or Spanish [detailed MMAS-8 questionnaires can be found elsewhere (18, 19). Self-reported medication adherence was measured by the MMAS-8 (18, 19). The MMAS-8 scale consists of eight items, of which summation yields a maximum of 8 points. Level of adherence to AI therapy was categorized as high, medium, and low (18, 19).

Volume 40, No. 2, page 859: At the end of Table I legend, the following sentence should be added:

Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, 14725 NE 20th St Bellevue, WA 98007, USA; dmoriskiy{at}gmail.com or trubow1{at}gmail.com.

Volume 40, No. 2, page 860: At the end of Table II legend, the following sentence should be added:

Volume 40, No. 2, page 862: On the left column, the following part should be removed:

The strength of our analysis include the licensing and utilization of the validated 8-item MMAS-8 adherence questionnaire as described previously (18, 19). In addition, the average duration of adjuvant endocrine therapy was 4.3 years, which allowed for assessment of long-term adherence to therapy.

Volume 40, No. 2, page 862: After the sentence ending with “nonadherence data (22, 23, 25, 26, 34, 36, 39)”, the following part should be added:

The strengths of our analysis include the licensing and utilization of the validated 8-item MMAS-8 adherence questionnaire as described previously (18, 19, 40, 41). In addition, the average duration of adjuvant endocrine therapy was 4.3 years, which allowed for assessment of long-term adherence to therapy.

Volume 40, No. 2, page 863: At the end of the Acknowledgements section, the following sentence should be added:

We thank Professor Donald E. Morisky, Department of Community Health Sciences, UCLA Fielding School of Public Health, Los Angeles, United States, for granting us the use of the copyrighted MMAS-8. Professor Morisky has worked his entire career in developing the very important instrument for medication-taking behavior measure. Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, 14725 NE 20th St Bellevue, WA 98007, USA; dmoriskiy{at}gmail.com.

Volume 40, No. 2, page 865: At the end of the References section, the following two References should be added:

40 Krousel-Wood MA, Islam T, Webber LS, Re RS, Morisky DE and Muntner P: New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care 15(1): 59–66, 2009. PMID: 19146365.

41 Morisky DE and DiMatteo MR: Improving the measurement of self-reported medication nonadherence: Final response. J Clin Epidemiol 64(3): 258–263, 2011. PMID: 21144706. DOI: 10.1016/j.jclinepi.2010.09.002

* All corrections have been inserted in the updated online version of the article.

Volume 41, No. 4, page 1938: On the left column, at the fourth paragraph of Patients and Methods section, the second sentence should read:

A secondary cytoreductive surgery was taken into consideration in patients in good general conditions and performance status < or = 1 and without ascites, diffuse bulky peritoneal nodules or peritoneal nodules confluent in plaques, mesenteric retraction, and extra-abdominal disease (except groin metastases) (3, 9, 34).

Volume 41, No. 4, page 1938: On the right column, at the third paragraph, the first sentence should read:

Freeware LIFEx software was used to enable calculation of several metabolic indices from the PET images imported in DICOM format on a dedicated personal computer (35).

Volume 41, No. 4, page 1939: On the right column, at the penultimate line, references (29, 35-42) should read (29, 36-43).

Volume 41, No. 4, page 1940: On the left column, at the third line, reference (35) should read (36).

Volume 41, No. 4, page 1941: On the left column, at the 4th line, reference (37) should read (38).

Volume 41, No. 4, page 1941: On the left column, at the 6th line, reference (36) should read (37).

Volume 41, No. 4, page 1941: On the right column, at the 1st line, reference (41) should read (42).

Volume 41, No. 4, page 1941: On the right column, at the 6th line, reference (42) should read (43).

Volume 41, No. 4, page 1942: On the left column, at the 1st line, references (38-40) should read (39-41).

Volume 41, No. 4, page 1942: On the left column, at the 6th line, reference (38) should read (39) and reference (40) should read (41).

Volume 41, No. 4, page 1942: On the left column, at the 13th line, reference (39) should read (40).

Volume 41, No. 4, page 1942: On the left column, at the 33rd line, reference (39) should read (40).

Volume 41, No. 4, page 1944: All References after 34 should read:

35 Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C, Pellot-Barakat C, Soussan M, Frouin F and Buvat I: LIFEx: A Freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res 78(16): 4786-4789, 2018. PMID: 29959149. DOI: 10.1158/0008-5472

36 Chung HH, Kwon HW, Kang KW, Park NH, Song YS, Chung JK, Kang SB and Kim JW: Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol 19(6): 1966-1972, 2012. PMID: 22124757. DOI: 10.1245/s10434-011-2153-x

37 Liao S, Lan X, Cao G, Yuan H and Zhang Y: Prognostic predictive value of total lesion glycolysis from ¹⁸F-FDG PET/CT in post-surgical patients with epithelial ovarian cancer. Clin Nucl Med 38(9): 715-720, 2013. PMID: 23856825. DOI: 10.1097/RLU.0b013e31829f57fa

38 Lee JW, Cho A, Lee JH, Yun M, Lee JD, Kim YT and Kang WJ: The role of metabolic tumor volume and total lesion glycolysis on ¹⁸F-FDG PET/CT in the prognosis of epithelial ovarian cancer. Eur J Nucl Med Mol Imaging 41(10): 1898-1906, 2014. PMID: 24852188. DOI: 10.1007/s00259-014-2803-x

39 Kim CY, Jeong SY, Chong GO, Son SH, Jung JH, Kim DH, Lee SW, Ahn BC and Lee J: Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer. Gynecol Oncol 136(3): 498-504, 2015. PMID: 25557270. DOI: 10.1016/j.ygyno. 2014.12.032

40 Vargas HA, Burger IA, Goldman DA, Miccò M, Sosa RE, Weber W, Chi DS, Hricak H and Sala E: Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. Eur Radiol 25(11): 3348-3353, 2015. PMID: 25916387. DOI: 10.1007/s00330-015-3729-9

41 Mayoral M, Fernandez-Martinez A, Vidal L, Fuster D, Aya F, Pavia J, Pons F, Lomeña F and Paredes P: Prognostic value of (18)F-FDG PET/CT volumetric parameters in recurrent epithelial ovarian cancer. Rev Esp Med Nucl Imagen Mol 35(2): 88-95, 2016. PMID: 26541072. DOI: 10.1016/j.remn.2015.08.005

42 Gallicchio R, Nardelli A, Venetucci A, Capacchione D, Pelagalli A, Sirignano C, Mainenti P, Pedicini P, Guglielmi G and Storto G: F-18 FDG PET/CT metabolic tumor volume predicts overall survival in patients with disseminated epithelial ovarian cancer. Eur J Radiol 93: 107-113, 2017. PMID: 28668403. DOI: 10.1016/j.ejrad.2017.05.036

43 Vallius T, Hynninen J, Kemppainen J, Alves V, Auranen K, Matomäki J, Oksa S, Virtanen J, Grénman S, Auranen A and Seppänen M: ¹⁸F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer. Eur J Nucl Med Mol Imaging 45(7): 1224-1232, 2018. PMID: 29476227. DOI: 10.1007/s00259-018-3961-z

*All corrections have been inserted in the updated online version of the article.